English 
Survodutide
Lithium Hydroxide
Description
Customer feedback
Basic Info.
Survodutide (also known as BI 456906) is a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, jointly developed by Boehringer Ingelheim and Zealand Pharma, and is intended to treat metabolic diseases such as obesity and non-alcoholic steatohepatitis.
Survodutide is a drug with an innovative mechanism of action and is expected to become a potential option for the treatment of obesity and metabolic-related diseases. Multiple clinical studies are underway to evaluate its safety and efficacy.
We have cooperated with experienced shipping forwarders for many years, they arrange the shipment. No matter by express, by air or by sea, we will track the course of the goods all the way, to make sure goods arrive at you on time and in good condition.
We have our own laboratory and production factory, and we can provide COA and MSDS for all products. The purity of the products is above 99%, and the quality of the products is guaranteed.
Since the establishment of our company, our products have been sold to countries and regions such as the United States, Europe, Australia, and South Africa, and we have received positive feedback from customers.
GET A QUOTE
Whether you have any questions about our products, please feel free to contact us, we will reply as soon as possible.
